Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...
The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...
This summary covers the latest health-related news, including FDA's approval of Spravato as a standalone depression treatment ...